Please login to the form below

Not currently logged in
Email:
Password:

Spinraza

This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

Roche gains EU PRIME status for Spinraza rival

Roche gains EU PRIME status for Spinraza rival

If risdiplam proves its worth in the clinic and gets approved, the drug could offer an alternative to Spinraza, an antisense oligonucleotide that has to be delivered by injection into the ... Roche reckons that risdiplam could have an advantage over

Latest news

  • Beneluxa: the future of European market access? Beneluxa: the future of European market access?

    Andrew McConaghie talks to Beneluxa’s Marcel van Raaij and Biogen’s Erik Smet about their groundbreaking deal on Spinraza and what it means for European market access. ... In the summer Beneluxa was able to announce its first successful deal with a

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    So what’s the deal for Spinraza? Spinraza is classified as an orphan drug for the treatment of spinal muscular atrophy (SMA), a rare neuromuscular disorder that occurs in one birth ... for further talks with Biogen, with draft guidance not recommending

  • Biogen picks up another drug from wide-ranging Ionis alliance Biogen picks up another drug from wide-ranging Ionis alliance

    " />. " />. Aims to follow success of Spinraza. Biogen’s longstanding collaboration with Ionis has already resulted in one marketed drug – Spinraza – and it’s now taken up rights to another for amyotrophic ... Ionis and Biogen’s collaboration

  • FDA fast tracks Novartis’ SMA gene therapy FDA fast tracks Novartis’ SMA gene therapy

    Gene therapy could be approved in first half of 2019, will challenge Biogen's Spinraza. ... Spinraza is priced at $750, 000 for the first year, and $350, 000 afterwards.

  • Orphan drugs from Biogen and Amicus win UK Prix Galien Orphan drugs from Biogen and Amicus win UK Prix Galien

    New medical technology category added for the first time. Amicus’ Galafold and Biogen’s Spinraza have won the two top prizes at the UK Prix Galien, the biennial awards which recognise ... Spinraza’s Prix Galien victory is well deserved and was the

More from news
Approximately 12 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to. ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    2015 and in the EU 2016) and Spinraza (for the treatment of spinal muscular atrophy, only approved in the US).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics